Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MicuRx will Receive $5.2 Million to Advance Drug-Resistant Antibiotic

publication date: Mar 6, 2018

MicuRx Pharma, a San Francisco-Shanghai anti-infective company, announced it will receive up to $5.2 million in non-dilutive financing from a global partnership: Combating Antibiotic Resistant Bacteria Accelerator (CARB-X). MicuRx will use the money to produce an IND and then conduct Phase I trials of MRX-8, a novel polymyxin antibiotic designed to treat multi-drug resistant Gram-negative infections. In preclinical tests, MRX-8 was effective with a lower incidence of the side effects caused by other products in the class. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital